NCT04051112已完成1 期
A Phase I Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Malignant Ascites
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- MTD
研究概览
简要总结
- The safety and tolerability of single-dose of SCB-313 will be evaluated by intraperitoneal injection;
- The safety and tolerability of repeated-dose of SCB-313 will be evaluated by intraperitoneal injection once a day for 3 days, and the maximum tolerated dose (MTD) of SCB-313 will be determined;
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed as malignant solid tumor.
- •Malignant ascites requiring puncture drainage evaluated by investigators, defined as:
- •if tumor cells are detectable in the ascites ,
- •if previous surgical operation reveals extensive abdominal cavity metastasis,
- •if there is image evidence of extensive metastasis in the abdominal cavity,
- •if it is determined by ascites routine and ascites biochemical examination as exudate.
- •Eastern Cooperative Oncology Group (ECOG) performance status: 0 to
- •Life expectancy of at least 12 weeks.
- •Age ≥ 18 years.
- •Body weight ≥ 45 kg and body mass index (BMI) >17 kg/m2
- •Adequate hematological function, defined as: (a) Platelet count ≥100×109/L, (b) Prothrombin time and activated partial thromboplastin time ≤ 1.5 times the upper limit of normal (ULN), (c) Absolute neutrophil count ≥1.5×109/L, and (d) Hemoglobin ≥ 9 g/dL.
- •Adequate renal function, defined as serum creatinine ≤ 2.0 times ULN and creatinine clearance > 50 mL/minute.
- •Adequate liver function, defined as: (a) Aspartate aminotransferase and alanine aminotransferase ≤ 3 times ULN for patients without liver metastases, or ≤ 5 times ULN in the presence of liver metastases, and (b) Bilirubin ≤ 2.0 times ULN, unless patient has known Gilberts syndrome.
- •Albumin ≥ 2.8 g / dL (patient can use albumin to meet the standard)
- •If the serum pregnancy test of a female patient with fertility is negative within 7 days prior to the initial administration, and she is willing to use effective birth control/contraception method for contraception within 6 months after discontinuation of SCB-313.( Female patients with fertility exclude women who have undergone sterilization or menopause, which is defined as a menstrual period that lasts for one year or more without any other medical reason.) All male and female patients with reproductive potential must agree to take effective contraceptive measures during the study period and within 6 months after discontinuation of SCB-
- •Note: Contraceptive methods considered to be effective include: complete abstinence, intrauterine devices, double barrier contraceptive methods (such as condom plus spermicide diaphragm), implanted contraceptives, hormonal contraceptives (contraceptives, implants agent, transdermal patch, hormonal vaginal device or injection for extended release), or the partner has removed the vas deferens and confirmed that it is azoospermia
- •Willing to attend follow-up visits according to study protocol.
排除标准
- •Loculated ascites not amenable to full drainage or benefit from abdominal treatment
- •Acute or chronic infection (such as tuberculosis) requiring antiviral or intravenous antibiotics within 2 weeks prior to enrollment.
- •Untreated central nervous system metastatic disease, leptomeningeal disease, or cord compression.
- •Residual adverse events (AEs) ≤ Grade 1 from previous treatment except alopecia.
- •Evidence or suspicion of relevant psychiatric impairment including alcohol or recreational drug abuse.
- •Myocardial infarction within 6 months prior to treatment, and/or prior diagnoses of congestive heart failure (New York Heart Association Class III or IV), unstable angina, unstable cardiac arrhythmia requiring medication, and/or long QT syndrome or QT/QTc interval >480 msec at baseline.
- •Uncontrolled hypertension defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg confirmed upon repeated measures.
- •Left ventricular ejection fraction < 50% as determined by echocardiography performed at screening
- •Hormone therapy or palliative extra abdominal radiotherapy within 1 week, prior anti-tumor therapy (chemotherapy) within 2 weeks, or other test drug within 4 weeks prior to enrollment.
- •Major surgery within 4 weeks prior to enrollment.
- •Patient with ileus within 30 days prior to screening.
- •Known portal vein obstruction (due to either prehepatic, hepatic, or posthepatic condition) which per Investigators judgement, is the primary or significant cause of ascites.
- •Positive serology test for human immunodeficiency virus type 1 and 2, or known history of other immunodeficiency disease.
- •Uncontrolled active hepatitis.
- •Scheduled participation in another clinical study involving an investigational product or device during the course of this study.
- •Previous treatment with a TRAIL-based therapy or Death Receptor (DR) 4/5 agonist therapy.
- •Known or suspected hypersensitivity to any component of the SCB
- •Any further condition which, according to the investigator, may result in undue risk of the patient by participating in the present study.
研究组 & 干预措施
SCB-313
Experimental
干预措施: SCB-313 (Drug)
结局指标
主要结局
MTD
时间窗: 28 days after first dosing
MTD for single and multiple doses of SCB-313
DLT
时间窗: 28 days after first dosing
Dose Limiting Toxicity (DLT)
AE/SAE
时间窗: 28 days after first dosing
The severity of the adverse events associated with SCB-313 treatment, the incidence of serious adverse events (SAE), and the severity and incidence of adverse events (TEAE) during the DLT-observation period developed in patients, and the classification is based on the National Cancer Institute General Adverse Event Terminology
次要结局
- Pharmacokinetics (Cmax)(Pre-dose(0 hour[hr]), 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr post-dose on Day 1 and Day 10)
- Pharmacokinetics ([AUC]0-24)(Pre-dose(0 hour[hr]), 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr post-dose on Day 1 and Day 10)
- Pharmacokinetics (tmax)(Pre-dose(0 hour[hr]), 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr post-dose on Day 1 and Day 10)
- Pharmacokinetics (AUC 0-inf)(Pre-dose(0 hour[hr]), 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr, 16 hr, 24 hr post-dose on Day 1 and Day 10)
- Immunogenicity(Up to 28 days after first dosing)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural EffusionMalignant Pleural EffusionNCT04123886Sichuan Clover Biopharmaceuticals, Inc.14
终止
1 期
A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal CarcinomatosisPeritoneal CarcinomatosisNCT04047771Sichuan Clover Biopharmaceuticals, Inc.10
终止
1 期
A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered IntravenouslyMucopolysaccharidosis III, Type B (MPS IIIB)Sanfilippo BNCT02618512Alexion Pharmaceuticals, Inc.3
终止
1 期
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS IMPS INCT02702115Sangamo Therapeutics3
已完成
1 期
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal MalignanciesPeritoneal MalignanciesNCT03443674Clover Biopharmaceuticals AUS Pty Ltd7